BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37627169)

  • 1. Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib.
    Nolan A; Raso C; Kolch W; Kriegsheim AV; Wynne K; Matallanas D
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular docking analysis reveals differential binding affinities of multiple classes of selective inhibitors towards cancer-associated KRAS mutants.
    Mullaguri SC; Akula S; Sahoo PS; Ashireddygari VR; Mupparapu V; Silveri R; Prasad Burra VLS; Kancha RK
    3 Biotech; 2022 Dec; 12(12):343. PubMed ID: 36353445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
    Lee A
    Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
    Roskoski R
    Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for Targeting KRAS: A Challenging Drug Target.
    Wadood A; Ajmal A; Rehman AU
    Curr Pharm Des; 2022; 28(23):1897-1901. PubMed ID: 35524675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
    Khan S; Budamagunta V; Zhou D
    Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations.
    Oyedele AK; Ogunlana AT; Boyenle ID; Ibrahim NO; Gbadebo IO; Owolabi NA; Ayoola AM; Francis AC; Eyinade OH; Adelusi TI
    Mol Divers; 2023 Aug; 27(4):1795-1807. PubMed ID: 36271195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition.
    Barrios-Bernal P; Lucio-Lozada J; Ramos-Ramírez M; Hernández-Pedro N; Arrieta O
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS: A Druggable Target in Colon Cancer Patients.
    Negri F; Bottarelli L; de'Angelis GL; Gnetti L
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
    Salmón M; Álvarez-Díaz R; Fustero-Torre C; Brehey O; Lechuga CG; Sanclemente M; Fernández-García F; López-García A; Martín-Guijarro MC; Rodríguez-Perales S; Bousquet-Mur E; Morales-Cacho L; Mulero F; Al-Shahrour F; Martínez L; Domínguez O; Caleiras E; Ortega S; Guerra C; Musteanu M; Drosten M; Barbacid M
    J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 36928090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Radil as a Ras binding partner and putative activator.
    Choi BH; Kou Z; Colon TM; Chen CH; Chen Y; Dai W
    J Biol Chem; 2021; 296():100314. PubMed ID: 33482197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS
    Chiou LW; Chan CH; Jhuang YL; Yang CY; Jeng YM
    J Biomed Sci; 2023 Jun; 30(1):50. PubMed ID: 37386628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS-targeted therapy in the treatment of non-small cell lung cancer.
    Yun J; Nakagawa R; Tham K
    J Oncol Pharm Pract; 2023 Mar; 29(2):422-430. PubMed ID: 35938195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of an LC-MS/MS method for the determination of sotorasib, a KRAS
    Wong P; Akrami A; Houk B; Vuu I; James CA
    Bioanalysis; 2022 Oct; 14(19):1281-1292. PubMed ID: 36473022
    [No Abstract]   [Full Text] [Related]  

  • 20. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
    Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
    Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.